Oncolys Biopharma Inc., of Tokyo, signed an exclusive, worldwide license agreement with Stabilitech Biopharma Ltd., of Burgess Hill, U.K., for Stabilitech's virus stability platform technology, Therm-SB. The main purpose of the in-licensing is to explore the possibility of drastically improved thermal stability and aggregation resistance of Oncolys' viroimmunotherapy pipeline, led by telomelysin. Under the agreement, a patent in relation to Therm-SB shall be granted to Oncolys, while Stabilitech is entitled to receive certain up-front/milestone fees and royalties according to development stages and sales performances, for which the details were not disclosed. Read More
The BIO International Convention 2018 in Boston and the American Society of Clinical Oncology (ASCO) meeting in Chicago, two of the important events in the biotech sector's annual calendar, are almost upon us. With that in mind, BioWorld Asia dives into the business of financial aspects of cancer. There is no doubt that transformative cancer therapies have attracted the attention of everyone, particularly investors, since they first burst on the scene a few years ago. Read More
BioWorld has reported on numerous advances in digital health, which are tantalizing examples of how digitization could transform health care, but it has long been clear lip service repetition of the term 'digital health' is not enough to deliver its potential: Read More
HONG KONG – China's contract drugmaking giant, Wuxi Biologics Inc., of Wuxi city, is actively expanding its global footprint, announcing plans to work with its Canadian partner on a brain cancer drug and opening its 10th global manufacturing facility in Singapore. Read More
HONG KONG – Newly launched Chinese biotech Brii Biosciences is looking to use an experienced management team, partnerships and $260 million in initial funding to bring innovative medicines to its home market faster. Its initial focus will be infectious diseases. Read More
SHANGHAI – Reform is not a word that the Chinese government shies away from. That has been particularly true for China's pharmaceutical industry. Since 2015, the government has been tackling widespread and impressive reforms, not the least of which was joining the International Council of Harmonization (ICH) last summer, accelerating the country's ability to align its system with international norms. Read More
